PRECLINICAL ALZHEMER'S DISEASE PREDICTS POST-STROKE DEMENTIA

临床前阿尔茨海默病可预测中风后痴呆症

基本信息

批准号：
8040960
负责人：
JOHN MORRIS
金额：
$ 30.97万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-03-15 至 2013-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8040960
关键词：
Accounting Acute Address Adult Affect Age Alzheimer&apos s Disease Amyloid Autopsy Biological Markers Biometry Blood Blood Vessels Cerebrospinal Fluid Cerebrum Clinical Cognitive Collection Consent DNA Data Data Set Dementia Disease Elderly Enrollment Etiology Evaluation Event Family Functional disorder Genes Genetic Polymorphism Image Individual Infarction Injury Ischemic Stroke Lesion Magnetic Resonance Imaging Medical History Monitor Neurodegenerative Disorders Neurological status Participant Pathogenesis Pathology Patients Personality Pittsburgh Compound-B Plasma Positron-Emission Tomography Principal Investigator Program Research Project Grants Proteins Recruitment Activity Relative (related person)Resources Risk Role Scanning Stroke Symptoms Telephone Testing Tracer Validation Variant base benzothiazole cerebrovascular clinical Diagnosis cohort experience functional status human old age (65+)ischemic lesion neuropathology neuropsychological post stroke pre-clinical programs

项目摘要

Project 1 will test the hypothesis that poststroke dementia is a function of preclinical Alzheimer's disease (AD). The prediction from this hypothesis is that poststroke dementia will be disproportionately represented in stroke individuals with preclinical AD in comparison with stroke individuals without preclinical AD. The Specific Aims of the project are to: 1. Over 3.5 years, enroll a cohort of 240 older adults, age 65 years and older, hospitalized with acute ischemic stroke and obtain baseline demographic data, medical history, neurological status, neuropsychological evaluation, prestroke cognitive and functional status, and blood for Project 2 (plasma) and Project 4 (DMA). 2. In this hospitalized cohort, obtain magnetic resonance imaging (MRI) to characterize cerebral ischemic lesions and positron emission tomography (PET) with the [11C]benzothiazole amyloid tracer, Pittsburgh Compound B (PIB), to determine the presence or absence of preclinical AD (as defined by a positive PIB scan). 3. Every three months after discharge, maintain telephone contact with the patient and their families to monitor intercurrent events and maintain compliance. 4. One year poststroke, assess all patients with the Clinical Core clinical and neuropsychological batteries and derive a Clinical Dementia Rating (CDR) for correlation with baseline PIB status (CDR > 0.5 will be considered evidence for dementia). 5. Obtain MRI one year poststroke to evaluate potential new ischemic lesions; obtain blood for plasma biomarkers (Project 2); enroll patients into Project 3; and follow all patients annually with clinical and cognitive assessments and obtain voluntary consent for autopsy. This project directly addresses the overall aim of the program project grant, to characterize preclinical AD. It further addresses the unresolved issue of why dementia occurs in some, but not all, individuals with stroke. This project uses resources from all Cores. It also interacts with each of the individual projects

项目 1 将检验中风后痴呆是临床前阿尔茨海默病的一个功能的假设（广告）。该假设的预测是中风后痴呆症的比例将不成比例患有临床前 AD 的卒中个体与没有临床前 AD 的卒中个体相比。该项目的具体目标是： 1. 3.5 年以上，招募 240 名年龄在 65 岁及以上、因急性重症监护病入院的老年人队列缺血性中风并获得基线人口统计数据、病史、神经状态、项目 2 的神经心理学评估、中风前认知和功能状态以及血液（等离子体）和项目 4 (DMA)。 2. 在这个住院队列中，获得磁共振成像 (MRI) 来表征脑部使用 [11C] 苯并噻唑淀粉样蛋白进行缺血性病变和正电子发射断层扫描 (PET) 示踪剂匹兹堡化合物 B (PIB)，以确定是否存在临床前 AD（如由正 PIB 扫描定义）。 3. 出院后每三个月与患者及其家属保持电话联系，监控并发事件并保持合规性。 4. 中风后一年，使用临床核心评估所有患者的临床和神经心理学电池并得出与基线 PIB 状态相关的临床痴呆评级 (CDR) (CDR > 0.5 将被视为痴呆症的证据）。 5.中风后一年进行MRI检查以评估潜在的新缺血性病变；获取血液以获取血浆生物标志物（项目2）；将患者纳入项目 3；并每年对所有患者进行临床和认知评估并获得尸检的自愿同意。该项目直接解决了该计划项目拨款的总体目标，以描述临床前 AD 的特征。它进一步解决了尚未解决的问题，即为什么某些（但不是全部）中风患者会出现痴呆症。该项目使用所有核心的资源。它还与每个单独的项目交互